FDA Approves LEUPROLIDE ACETATE — UBI Pharma Inc.

# FDA Approves UBI Pharma's Generic Leuprolide Acetate Injection The FDA has approved UBI Pharma Inc.'s abbreviated new drug application (ANDA) for leuprolide acetate subcutaneous injection, marking a new entrant in the competitive generic market for this widely-used hormone therapy. The approval is expected to increase price competition and improve patient access to this treatment for conditions including prostate cancer, endometriosis, and uterine fibroids.